Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly (NYSE: LLY) delivered a gain worthy of a technology growth stock last year. The pharma giant’s…
FDA commissioner’s drug review plan sparks alarm
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…
Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…
How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog.…
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy
This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S.…
Six economic flashpoints to watch out for in 2026 – The Irish Times
The global economy showed remarkable resilience in 2025 despite significant trade tensions and policy uncertainty related to US…
China’s new commercial insurance model could broaden access to Alzheimer’s drugs
China’s new commercial insurance formulary looks to expand patient access to Alzheimer’s disease medicines from Eli Lilly and…
Novo’s Wegovy pill to test demand from consumers with cash
LONDON, Dec 23 (Reuters) – Novo Nordisk’s newly approved weight-loss pill version of Wegovy will be a test…
Eli Lilly’s pill solves the biggest problem with weight loss
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly…
Eli Lilly Scores Another Major Win: Time to Buy?
Eli Lilly’s next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should…